Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 1
2005 1
2007 2
2008 1
2009 1
2010 2
2011 1
2012 2
2013 3
2014 3
2015 5
2016 1
2017 2
2018 3
2019 8
2020 1
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Results by year
Filters applied: . Clear all
Page 1
Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases.
Mahmud Z, Asaduzzaman M, Kumar U, Masrour N, Jugov R, Coombes RC, Shousha S, Hu Y, Lam EW, Yagüe E. Mahmud Z, et al. Among authors: yague e. Biochem Pharmacol. 2019 May;163:391-403. doi: 10.1016/j.bcp.2019.03.009. Epub 2019 Mar 9. Biochem Pharmacol. 2019. PMID: 30862505 Free article.
FOXA1 is a determinant of drug resistance in breast cancer cells.
Kumar U, Ardasheva A, Mahmud Z, Coombes RC, Yagüe E. Kumar U, et al. Among authors: yague e. Breast Cancer Res Treat. 2021 Apr;186(2):317-326. doi: 10.1007/s10549-020-06068-5. Epub 2021 Jan 8. Breast Cancer Res Treat. 2021. PMID: 33417085 Free PMC article.
35 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page